Data under review. Our nightly checks found a problem in this company's reported figures on Oct 23, 2026, so we are not showing its score, ratios or statements for now. The figures come back after they pass the checks two nights in a row. The price and chart are live.
CryoPort (CYRX) News
What's actually happening: chronological and provenance-stamped. News is context, not a signal.
93,646 CryoPort, Inc. $CYRX Shares Sold by CenterBook Partners LP
CenterBook Partners LP lessened its stake in shares of CryoPort, Inc. (NASDAQ: CYRX) by 54.6% in a recent quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 77,94…
Cryoport, Inc. is downgraded from Hold to Sell due to valuation concerns despite strong revenue growth. CYRX's balance sheet improved after the CRYOPDP sale, with net cash of $204.8 million, but profitability remains elu…
CryoPort NASDAQ: CYRX raised its full-year 2026 revenue outlook after reporting third-quarter revenue growth of 14%, supported by demand for its cell and gene therapy services and cryogenic products.…
CryoPort, Inc. (CYRX) Reports Q3 Loss, Tops Revenue Estimates
CryoPort, Inc. (CYRX) came out with a quarterly loss of $0.25 per share versus the Zacks Consensus Estimate of a loss of $0.19. This compares to a loss of $0.18 per share a year ago.…
● PRNewsWireNov 5, 2026 · 16:05 ETCOMPANY'S OWN WORDS
Cryoport Reports Third Quarter 2026 Financial Results
Third quarter revenue grew 14% year-over-year to $50.2 million Commercial Cell and Gene Therapy revenue increased 20% year-over-year Supporting a record 788 global clinical trials and 23 commercially approved cell and ge…
● PRNewsWireOct 22, 2026 · 08:00 ETCOMPANY'S OWN WORDS
Cryoport to Report Third Quarter 2026 Financial Results on November 5, 2026
NASHVILLE, Tenn., Oct. 22, 2026 /PRNewswire/ -- Cryoport, Inc. (Nasdaq: CYRX) ("Cryoport" or the "Company"), a leading global provider of integrated temperature-controlled supply chain solutions for the life sciences, to…
Cryoport: Strong Pipeline Of Cell And Gene Therapy Approvals
Cryoport, Inc., rated BUY, is up 82% YTD, driven by robust cell and gene therapy (CGT) commercialization and pipeline momentum. CYRX returned to adjusted EBITDA profitability in 2Q26, with strong Life Science Services gr…
Article counts from the last market-wide feed page, across every symbol we track and not just CYRX · day move from the quote feed. Equal counts are listed alphabetically, not ranked. Coverage ≠ importance.
The feed is purely chronological. No materiality ranking, no hidden sentiment score. Timestamps are publisher-reported and arrive with no timezone, so they are read and shown on the US market clock (ET); thumbnails come from each article's image field; day moves from the quote feed. Copies of the same story are collapsed on link or normalized headline, and a company's press release is kept over any syndicated copy of it; "company's own words" means the release title leads with the company's name and the wire names no other organisation first as its issuer; "earnings-tied" is a keyword match while a report date is upcoming. Not investment advice.